İbrahim DUMAN, Erbil ERGENEKON, Serdar ARISAN, Cem SÖNMEZ, Ayhan DALKILIÇ, Turhan ÇAŞKURLU

E-cadherin immunohistochemistry for prostate cancer early diagnosis and monitoring of illness

Prostat kanseri, hemen hemen en sık rastlanılan erkek kanserlerinden bir tanesi olup, çok yaygındır. Halen doğal prognostik faktörleri prostat kanseri için aydınlatılamamıştır. Bu yüzden acilen agresivite ve prognoz ile moleküler mekanizmaların bulunmasına ihtiyaç vardır. E-cadherin geni 16q22 kromozomu üzerinde 120kDa büyüklüğünde ve Ca2+ bağlı adezyon molekülleri ailesindendir. E-cadherinin fonksiyonel kaybı kanser hücrelerinde tumor gelişimi ve progresyonuna neden olur. Bu çalışmada prostatectomy sonrasında Gleason skorlamalan ve e-cadherin aktivitesi karşılaştırılmış ve prostat kanseri için E-cadherin moleküllerinin önemi ortaya konmaya çalışılmıştır.

Prostat kanseri erken tanı ve hastalığın izlenmesinde e-cadherin immunohistokimya uygulanması

Prostate cancer (pCA) is the most commonly diagnosed noncutaneous malignancy in men world wide. The natural history of prognostic factors involved in prostate cancer are not clearly defined. Hence, molecular parameters able to accurately assess the aggressiveness and the metastatic potential of the cancer are urgently needed. The E-cadherin gene, on chromosome 16q22 encodes for transmembran 120 kDa glycoprotein belonging to the group of Ca2+ depending homophilic cell adhesion molecules (CAMs). Loss of E-cadherin function in cancer cells likely plays at least two different roles in tumor, development and progression. In this study after prostatectomy procedure, the prostate specimens were analyzed for E-cadherin activity and compare with Gleason scores. It is aimed to reveal the prognostic importance of E-cadherin molecules in pCA.

PDF

___

American Cancer Society: Cancer Facts and Figures-2002. Atlanta, Ga: American Cancer Society, 2002
Arısan S. Prostate cancer and importance of tumor marker studies.j of Cell and Mol Biol. 1: 49-51, 2003.
Buyuktuncer D, Arisan S, Ozdilli K. Ecadherin molecular mechanism in prostate cancer.j of Cell and Mol Biol. 2: 57-64, 2003.
Cano AMA, Perez-Moreno I, Rodrigo A, Locascio MJ, Blanco MG, del Barrio F, Portillo MA, Nieto. The transcription factor snail controls epithelial mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2: 76-83, 2000.
Chen CL, Liu SS, Ip S-M. E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur JCancer. 2: S0959 8049(02)00175-2, 2003.
DeMarzo AM, Knudsen B, Chan-Tack K and Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology. 53: 707-713, 1999.
El-Hariry I, Pignatelli M, Lemoine NR. FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines. Br J Cancer. 84: 1656-1663, 2001.
Gao X, Porter AT, Grignon DJ, Diagnostic and prognostic markers for human prostate cancer. Prostate. 31: 264-281, 1997.
Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 153: 333-339,1998.
Jiang WG, Puntis MCA, Hallett MB. The molecular and cellular basis of cancer invasion and metastasis and its implications for treatment. BrJSurg. 81: 1576-90,1994.
Mason MD, Davies G, Jiang WG, Cell adhesion molecules and adhesion abnormalities in prostate cancer, Critical Reviews in Oncology/Hematology. 41: 1-28, 2002.
Nathke IS, Hinck L, Swedlow JR, Papkoff J and Nelson WJ. Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. j Cell Biol. 125: 1341-1352, 1994.
Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma, Nature. 392: 190-193, 1998.
Poser I, D. Dominguez, A.G. de Herreros, A. Varnai, R. Buettner, A.K. Bosserhoff, Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail, j Biol Chem. 27: 24661-24666, 2001.
Tomita K, van Bokhoven A, van Leenders GJLH, Ruijter ETG, Jansen CFJ, Bussemakers MJG, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res. 60: 3650-3654, 2000.
Vleminckx KL, Vakaet J, Mareel M. Genetic manipulation of E-cadherin expression by epithelial tumour cells reveals an invasion suppressor role. Cell. 66: 107-119, 2001.
Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM and Schalken JA. Relation between aberrant a-catenin expression and loss of E-cadherin function in prostate cancer. IntJ Cancer. 74: 374-311, 1997.
Yagi T and Takeichi M. Cadherin superfamily genes: Functions, genomic organization, and neurologic diversity. Genes Dev. 14: 1169-1180, 2000.